Portfolio company
Simplexia
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops a vaccine against herpes simplex virus type 2 for patients with genital herpes infections.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Aelix
The company develops therapeutic vaccines to treat and eradicate human immunodeficiency virus infections for patients.
Curevo Vaccine
This clinical-stage biotechnology company develops next-generation subunit vaccines for shingles and chickenpox to serve adults and immunocompromised patients.
MinervaX
This biotechnology company develops a protein-based vaccine against Group B Streptococcus for pregnant women, newborns, and older adults.
Aelix Therapeutics
Aelix Therapeutics develops therapeutic vaccines for patients living with HIV to help control the virus without lifelong antiretroviral therapy.
Antiva Biosciences
This company develops topical antiviral treatments for high-risk human papillomavirus infections and pre-cancerous cervical lesions in women.
Pharmexa A/S
This company develops active immunotherapy and peptide vaccines for patients with cancer, chronic illnesses, and infectious diseases.
Curevo
This clinical-stage biotechnology company develops non-mRNA subunit vaccines to prevent shingles and chickenpox in adults and children.
Humane Genomics
This company develops synthetic oncolytic viral therapies to treat cancer patients by engineering viruses that selectively infect and destroy malignant cells.
